FNA - Earnings announcements

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Chadi Chahine has been appointed Chief Financial Officer and Executive Vice-President of Supply Chain Operations, effective August 5, 2024. The Company also reported financial results for the quarter ended June 30, 2024, and narrowed its 2024 net revenue guidance. Recent Business Updates Strengthened executive leadership team with appointment of Chadi Chahine as CFO & EVP Supply Chain Operations, effective August 5, 2024 Recorded global revenue of $61.0 million in the second quarter, representing 19.6% and 19.7% r

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 389675. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance. First Quarter 2024 Financial Results Consolidated net revenue for the first quarter of 2024 was a record $61.1 million, representing 17.4% reported and constant currency growth over the first quarter of 2023. Foreign currency impact on first quarter 2024 reported net revenue growth was not material. U.S. net revenue for the first quarter of 2024 was $51.1 million, representing growth of 13.5% over the first quarter of 20

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance. Fourth Quarter and Full Year 2023 Financial Results Consolidated net revenue for the fourth quarter of 2023 was $60.6 million, representing 17.6% and 17.3% reported and constant currency growth, respectively, compared to the fourth quarter of 2022. Consolidated net revenue for the full year 2023 was $216.4 million, representing 19.3% and 19.7% reported and constant currency growth, respectively, compared to the full y

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 593140. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.pa

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance. Third Quarter 2023 and Nine Months Ended September 30, 2023 Financial Results Consolidated net revenue for the third quarter of 2023 was $52.8 million, representing 14.7% and 14.5% reported and constant currency growth, respectively, compared to the third quarter of 2022. Consolidated net revenue for the nine months ended September 30, 2023 was $155.8 million, representing 20.0% and 20.6% reported and constant currency

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (646-904-5544) for international callers, using conference ID: 308457. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance. Second Quarter 2023 and Six Months Ended June 30, 2023 Financial Results Consolidated net revenue for the second quarter of 2023 was $51.0 million, representing 20.0% and 20.8% reported and constant currency growth, respectively, compared to the second quarter of 2022. Consolidated net revenue for the six months ended June 30, 2023 was $103.0 million, representing 22.9% and 23.9% reported and constant currency growth, respec

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (888-330-2446) for domestic callers or (240-789-2732) for international callers, using conference ID: 4439305. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. Th

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance. First Quarter 2023 Financial Results Consolidated net revenue for the first quarter of 2023 was a record $52.0 million, representing 25.8% and 27.1% reported and constant currency growth, respectively, over the first quarter of 2022. U.S. net revenue for the first quarter of 2023 was $45.0 million, representing growth of 24.9% over the first quarter of 2022. International net revenue for the first quarter of 2023 was

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2023 after market close on Thursday, May 4, 2023. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (929-526-1599) for international callers, using conference ID: 007721. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The webc

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2022. Fourth Quarter and Full Year 2022 Financial Results Consolidated net revenue for the fourth quarter of 2022 was $51.5 million, representing 20.4% and 22.1% reported and constant currency growth, respectively. Consolidated net revenue for the full year 2022 was $181.4 million, representing 23.0% and 24.5% reported and constant currency growth, respectively. U.S. net revenue for the fourth quarter and full year of 2022 was $45.3 million and $158.1 million, respectively, con

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, March 2, 2023. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (929-526-1599) for international callers, using conference ID: 798665. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The webcast will b

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2022 and increased its 2022 net revenue guidance. Financial Highlights Net revenue $46.0 million for the third quarter of 2022, a quarterly net revenue record, representing reported growth of 28% over the third quarter of 2021. Foreign currency headwinds reduced quarterly net revenue and net revenue growth by approximately $0.8 million and 2.1 percentage points, respectively, as compared to the prior year quarter. U.S. quarterly revenue was a record $40.0 million, representing growth

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (929-526-1599) for international callers, using conference ID: 703484. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The webcast will be arc

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue guidance. Financial Highlights Net revenue $42.5 million for the second quarter of 2022, representing growth of 19% over the second quarter of 2021. Strengthening of the U.S. dollar reduced second quarter 2022 net revenue growth by 140 basis points as compared to the second quarter of 2021. U.S. revenue for the second quarter of 2022 was $36.8 million, representing growth of 19% over the second quarter of 2021. Growth in the quarter was driven primarily

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2022 and updated its 2022 revenue guidance. Financial Highlights Net revenue $41.4 million for the first quarter of 2022, representing growth of 25% over the first quarter of 2021 U.S. revenue for the first quarter of 2022 was $36.0 million, representing growth of 24% over the first quarter of 2021. Despite Covid-19 headwinds in January and early February, performance in the quarter was driven by continued strong commercial execution and contribution from new products, an expanded surgeon

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (646-904-5544) for international callers, using conference ID: 990038. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The webcast will be archived and avai

Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021. 2021 Highlights Net revenue $42.8 million for the fourth quarter of 2021, representing 22% growth over the fourth quarter of 2020, driven by increased revenue per US surgeon and US sales force expansion, plus strong growth in South Africa and the UK Net revenue $147.5 million for the twelve months ended December 31, 2021, representing 33% growth over 2020 Gross margin 81.7% for the fourth quarter 2021 compared to 72.3% for the fourth quarter of 2020

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 8, 2022. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (929-526-1599) for international callers, using conference ID: 902702. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The webcast will be

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and nine months ended September 30, 2021. Financial Highlights Net revenue $35.9 million for the third quarter of 2021, representing 18% and 45% growth over the third quarters of 2020 and 2019, respectively, driven by sales channel expansion and new product revenue Net revenue $104.7 million for the nine months ended September 30, 2021, representing 38% and 41% growth over the nine months ended September 30, 2020 and 2019, respectively, driven by sales channel expansion and new product revenue Gross mar

Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter of 2021 before market open on Monday, November 22, 2021. The company's management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (929-526-1599) for international callers, using conference ID: 353414. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The webcast will be archived